Anatomy of a successful 2026 listing: what City Therapeutics got right
On October 16, 2026, a two-year-old biotechnology company with no approved products, no meaningful revenue, and a net loss of $58.5 million for its last fiscal year began trading on the Nasdaq Global Market and finished its first day up 28 percent. City Therapeutics, a Cambridge, Massachusetts developer of RNA interference medicines, sold 11.1 million shares at $18.00, the exact midpoint of its marketed range, raised $200 million against an original plan of $158 million, and opened for trading at $23.00. By the close, the market valued the company near $1.2 billion. In a year when regulators and exchanges have been tightening listing standards and the small end of the IPO market has thinned dramatically, a debut like this is worth studying line by line. Not because every company can raise $200 million, but because the structure of the deal explains why it worked, and that structure scales. Companies preparing a listing at a tenth of this size face the same tests and can copy the same moves.